导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.50% | 2867/4773 |
| 近一周 | -0.68% | 709/5458 |
| 近一月 | -4.84% | 3116/5421 |
| 近一季 | 12.14% | 158/5205 |
| 近半年 | -1.39% | 1810/4920 |
| 近一年 | -14.87% | 3705/4361 |
| 近两年 | 23.40% | 2599/2954 |
| 近三年 | -16.09% | 2110/2253 |
| 成立以来 | 1.68% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.92% 2968/4961 |
-7.07% 3768/5312 |
- - |
- - |
| 2025 | 3.89% 3085/4813 |
3.00% 1219/3635 |
-1.60% 3225/4076 |
18.24% 2324/4524 |
-13.31% 4288/4813 |
| 2024 | -16.47% 2504/3463 |
-14.52% 2523/2808 |
-11.16% 2510/3014 |
22.73% 447/3129 |
-10.37% 2983/3463 |
| 2023 | -23.10% 1951/2656 |
-2.40% 1976/2280 |
-15.07% 2246/2385 |
-1.42% 517/2515 |
-5.90% 1544/2655 |
| 2022 | -24.80% 1259/2207 |
-17.29% 1195/1919 |
3.58% 1131/2016 |
-19.04% 1748/2113 |
8.42% 264/2208 |
| 2021 | -13.92% 1140/1822 |
-3.45% 807/1255 |
23.81% 113/1330 |
-17.92% 1413/1466 |
-12.27% 1625/1822 |
| 2020 | 87.29% 27/1250 |
13.87% 6/1028 |
41.11% 4/1067 |
3.57% 977/1164 |
12.54% 454/1184 |
| 2019 | - - |
- - |
- - |
13.11% 27/850 |
5.38% 727/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华宝中证医疗ETF VS. 长安沪深300非周期A(740101) |